Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;17(4):1215-1238.
doi: 10.1007/s12015-020-10114-6. Epub 2021 Jan 11.

Advances in Liver Cancer Stem Cell Isolation and their Characterization

Lu Liu  1 , Jürgen Borlak  2
Affiliations
Review

Advances in Liver Cancer Stem Cell Isolation and their Characterization

Lu Liu et al. Stem Cell Rev Rep. 2021 Aug.

Abstract

Over the last decade research on cancer stem cells (CSC) significantly contributed to a better understanding of tumor biology. Given their similarity to normal stem cells, i.e. self-renewal and pluripotency the need arises to develop robust protocols for the isolation and characterization of CSCs. As with other malignancies, hepatic tumors are composed of a heterogeneous population of cells including liver cancer stem cells (LCSC). Yet, a precise understanding of why stem cells become cancerous is still lacking. There is unmet need to develop robust protocols for the successful isolation of LCSCs from human tissue resection material as to assist in the development of molecular targeted therapies. Here we review the research progress made in the isolation and characterization of LCSCs by considering a wide range of cell surface markers and sorting methods, as applied to side populations, microsphere cultures and the gradient centrifugation method. We emphasize the different fluorescence activated cell sorting methods and the possibility to enrich LCSCs by immunomagnetic beads. We review the specificity of functional assays by considering ABCG transporter and ALDH1 enzyme activities and evaluate the in vivo tumorigenicity of LCSCs in highly sensitive bioassays. Finally, we evaluate different LCSC markers in association with viral and non-viral liver disease and explore the potential of novel drug delivery systems targeting CD133, EpCAM, CD13 and CD90 for the development of molecular targeted therapies. Graphical Abstract.

Keywords: Cancer stem cells characterization; Cancer stem cells isolation; Drug treatment; Liver cancer; Targeted drug delivery.

PubMed Disclaimer

References

    1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492 . - DOI
    1. Covey, A. M. (2018). Hepatocellular carcinoma: updates to screening and diagnosis. Journal of the National Comprehensive Cancer Network, 16(5S), 663–665. https://doi.org/10.6004/jnccn.2018.0052 . - DOI - PubMed
    1. Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., Yu, H., Lin, H., & Cai, X. (2015). Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters, 367(1), 1–11. https://doi.org/10.1016/j.canlet.2015.06.019 . - DOI - PubMed
    1. Nguyen, L., Chapel, S., Tran, B. D., & Lacy, S. (2019). Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. Journal of Pharmacokinetics and Pharmacodynamics, 46(6), 577–589. https://doi.org/10.1007/s10928-019-09659-y . - DOI - PubMed
    1. Yu, C. C., Huang, S. Y., Chang, S. F., Liao, K. F., & Chiu, S. C. (2020). The synergistic anti-cancer effects of NVP-BEZ235 and regorafenib in hepatocellular carcinoma. Molecules, 25(10). https://doi.org/10.3390/molecules25102454 .

Substances

LinkOut - more resources